Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 8,927,298 | 5,317,288 | 6,782,864 | 5,799,860 | 4,896,417 | 31,723,727 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 8,927,298 | 5,317,288 | 6,782,864 | 5,799,860 | 4,896,417 | 31,723,727 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 2,564,698 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 29,159,029 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 8,927,298 | 5,317,288 | 6,782,864 | 5,799,860 | 4,896,417 | 31,723,727 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 73,774 | 45,040 | 54,832 | 92,900 | 249,077 | 515,623 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 35,890 | 184,297 | 113,635 | 49,115 | 28,655 | 411,592 |
| 11 | Total support. Add lines 7 through 10 | 32,650,942 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2023 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2023 |
(iii) Distributable Amount for 2023 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2023 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2023 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2023: | ||||
| a From 2018....... | ||||
| b From 2019....... | ||||
| c From 2020....... | ||||
| d From 2021....... | ||||
| e From 2022....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2023 distributable amount | ||||
|
i
Carryover from 2018 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2023 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2023 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2023, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2023. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2024. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2019..... | ||||
| b Excess from 2020..... | ||||
| c Excess from 2021..... | ||||
| d Excess from 2022..... | ||||
| e Excess from 2023..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| Schedule A, Part II, Line 10 Other Income | DESCRIPTION - OTHER, COLUMN A - 35890.0, COLUMN B - 184297.0, COLUMN C - 113635.0, COLUMN D - 49115.0, COLUMN E - 28655.0, COLUMN F - 411592.0; |
| Software ID: | 23017437 |
| Software Version: | 2023v5.1 |
| Return Reference | Explanation |
|---|---|
| Form 990, Part III, Line 4a | PUBLIC AND PATIENT EDUCATION: AS PART OF OUR THINK LIVER THINK LIFE INITIATIVE, ALF MADE GREAT STRIDES IN RAISING AWARENESS ABOUT FATTY LIVER DISEASE AND SCREENING AT-RISK INDIVIDUALS FOR FATTY LIVER. WE CREATED AN ONLINE QUIZ TO HELP PEOPLE UNDERSTAND IF THEY ARE AT RISK FOR FATTY LIVER DISEASE. AS OF DECEMBER 2023, 7,500 PEOPLE HAD TAKEN THE QUIZ AND 90% HAD SHOWN RISK FACTORS FOR FATTY LIVER DISEASE. WE DEVELOPED NEARLY 50 NEW PARTNERSHIPS WITH FEDERALLY QUALIFIED HEALTH CENTERS (FQHCS) AND COMMUNITY CLINICS TO CONDUCT FATTY LIVER TESTING. TO DATE, 1,204 PEOPLE PARTICIPATED IN SCREENINGS TO TEST FOR THE PREVALENCE OF FATTY LIVER DISEASE. OF THOSE TESTED, 60% HAVE A SCORE OF S1 OR HIGHER AND 33% HAVE AN S2 OR HIGHER (WHICH MEANS THAT THE DISEASE IS PRESENT). THIS DATA SHOWS WE HAVE BEEN SUCCESSFUL IN TARGETING INDIVIDUALS WHO HAVE UNDIAGNOSED LIVER DISEASE AND CONNECTING THEM TO CARE. ALF HOSTED AN AUTOIMMUNE LIVER DISEASE FORUM. THERE WERE 400 REGISTRANTS AND OVER 180 ATTENDEES AT THE EVENT. THIS FORUM BROUGHT TOGETHER PATIENTS, CAREGIVERS, HEPATOLOGISTS, PRIMARY CARE PROVIDERS, PATIENT ADVOCACY ORGANIZATION PERSONNEL, AND INDUSTRY REPRESENTATIVES. A PATIENT BILL OF RIGHTS, EXECUTIVE SUMMARY AND PATIENT TOOLKIT WILL BE CREATED AND PUBLISHED AFTER THE EVENT. ALF'S PEDIATRIC LIVER DISEASE INFORMATION CENTER WAS LAUNCHED ON FEBRUARY 28, 2023. THESE ONLINE RESOURCES FEATURE DISEASE-SPECIFIC INFORMATION, PATIENT STORIES, VIDEOS, AND EDUCATIONAL RESOURCES. HTTPS://LIVERFOUNDATION.ORG/LIVERDISEASES/ PEDIATRIC-LIVER-INFORMATION-CENTER/ ON FEBRUARY 28TH, RARE DISEASE DAY, WE RELEASED THE OFFICIAL RARE LIVER DISEASE PATIENT BILL OF RIGHTS AND EXECUTIVE SUMMARY FROM THE 2022 RARE LIVER DISEASE SUMMIT. THE PATIENT BILL OF RIGHTS ENCOURAGES RARE DISEASE PATIENTS TO ADVOCATE FOR THEMSELVES AND PROMOTE A BETTER WORKING RELATIONSHIP WITH THE MEMBERS OF THEIR HEALTHCARE TEAM. ALF SUPPORTED THE CDC'S DIVISION OF VIRAL HEPATITIS IN LAUNCHING THEIR PILOT COLLECTION PROCESS. WHERE THE CDC WILL BE CONDUCTING INTERVIEWS WITH CURRENT AND FORMER HEPATITIS C PATIENTS TO COLLECT TESTIMONIALS THAT CAN BRING AWARENESS TO WHAT HELPS AND/OR PREVENTS PATIENTS FROM RECEIVING HEPATITIS C TREATMENT. ALF SHARED BEST PRACTICES FOR DEVELOPING PATIENT STORIES AND RECRUITING PARTICIPANTS. ALF WILL CONTINUE TO SUPPORT THE CDC WHEN THIS PROJECT IS APPROVED. ALF HAS PARTNERED WITH PLATFORM Q ON A PROGRAM ENTITLED, "OVERCOMING STIGMA AND ADVOCATING FOR EQUITABLE CARE IN LIVER CANCER." A PANEL OF LIVER CANCER SPECIALISTS FROM MEMORIAL SLOAN KETTERING PROVIDED INFORMATION ON NEW AND EMERGING TREATMENTS FOR LIVER CANCER. IN MAY, ALF HOSTED A HEPATITIS C WEBINAR IN COLLABORATION WITH THE CENTERS FOR DISEASE CONTROL AND PREVENTION DIVISION OF VIRAL HEPATITIS. WE HAD 695 PEOPLE REGISTERED AND 172 LIVE ATTENDEES. THIS WEBINAR PROVIDES INFORMATION ABOUT THE CDC VITAL SIGNS REPORT ON NEWLY-REPORTED CASES OF HEPATITIS C AND UPDATED HEPATITIS C SCREENING RECOMMENDATIONS, HOW TO PARTNER TO INCREASE HEPATITIS C TREATMENT AND CDC CANCER CONTROL PROGRAMS. THE AMERICAN LIVER FOUNDATION HOSTED A TWO-DAY END-STAGE LIVER DISEASE ROUNDTABLE TO DISCUSS ISSUES RELATED TO END STAGE LIVER DISEASE. THIS MEETING WILL FOCUS ON TOPICS SUCH AS COMPLICATIONS OF END-STAGE LIVER DISEASE, SUPPORT FOR PATIENTS AND CAREGIVERS, AND GAPS IN RESEARCH FOR END-STAGE LIVER DISEASE. LIVER HEALTH TODAY, ALF'S MONTHLY E-NEWSLETTER FOR PATIENTS AND CAREGIVERS, WAS DISTRIBUTED MONTHLY TO 225,000 PATIENTS, SUPPORTERS, AND VOLUNTEERS IN 2023. THE 2023 LIVER CANCER CONFERENCE WAS PRESENTED VIRTUALLY TO 272 ATTENDEES, AND THE RECORDING OF THE CONFERENCE AND ITS SESSIONS HAS BEEN VIEWED 785 AND 1,109 TIMES, RESPECTIVELY. ALF UPDATED AND CREATED NEW WEB CONTENT ON A VARIETY OF LIVER DISEASE TOPICS. THE WEBSITE WAS VISITED BY ALMOST 2.3 MILLION PEOPLE IN 2023. |
| Form 990, Part III, Line 4b | PATIENT SUPPORT: THESE THREE AREAS OF WORK HAVE RESULTED IN FULFILLMENT OF MISSION-RELATED GOALS IN 2023. RESPONDED TO 3,625 HELPLINE CALLS, LIVE CHATS AND EMAILS FROM PATIENTS, CAREGIVERS AND THE PUBLIC. HOSTED FACEBOOK SUPPORT GROUPS FOR PEOPLE WITH PRIMARY BILIARY CHOLANGITIS, LIVER CANCER, NASH, AND PEDIATRIC LIVER DISEASES. IN 2023, THE CUMULATIVE TOTAL OF PARTICIPATING FACEBOOK SUPPORT GROUP MEMBERS WAS 8,909. INITIATED PLANNING AND DEVELOPMENT OF ITS "SHARING THE JOURNEY" SERIES OF VIRTUAL SUPPORT GROUPS FOR PATIENTS, CAREGIVERS, AND LIVER TRANSPLANT RECIPIENTS FOR LAUNCH IN MARCH 2024. BEGAN LAYING THE GROUNDWORK FOR ITS "CARING CONNECTIONS" PEER-TO-PEER MENTORING PROGRAM, WHICHWILL LAUNCH IN THE SUMMER OF 2024. PRESENTED PEDIATRIC LIVER DISEASE WEBINARS AND DEVELOPED A TOOLKIT FOR PARENTS OF CHILDREN DIAGNOSED WITH LIVER DISEASE, SPECIFICALLY BILIARY ATRESIA. IDENTIFIED MEDICAL PROFESSIONALS TO SERVE AS AN EDUCATIONAL PROVIDER FOR VETERAN AFFAIRS AND MODERATOR OF ALF'S PBC FACEBOOK SUPPORT GROUP. RECRUITED NEW ORGANIZATIONAL PARTNERS THAT SERVE THE HISPANIC COMMUNITY AND ASSISTED WITH THE TRANSLATION OF ALF PRINT MATERIALS FROM ENGLISH TO SPANISH. |
| Form 990, Part III, Line 4c | COMMUNITY SERVICE: ALF CONDUCTS ADVOCACY WORK ON BEHALF OF THE PATIENT COMMUNITY THROUGHOUT THE YEAR, ACTIVELY RAISING AWARENESS OF PERTINENT LEGISLATION AFFECTING THE LIVER COMMUNITY AMONG THE FEDERAL GOVERNMENT. PARTNERED WITH 2,356 PATIENT ADVOCATES WHO FURTHER ALF'S MISSION THROUGH NATIONAL LEGISLATIVE CALLS TO ACTION AND SENDING LETTERS TO THEIR CONGRESS MEMBERS. PRIORITIES INCLUDED: *PROGRAMMATIC FUNDING OF $1.5M TO FUND A STUDY ON NONALCOHOLIC FATTY LIVER DISEASE THROUGH THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE. THIS FUNDING, THE FIRST OF ITS KIND, WAS APPROVED IN THE 2025 FEDERAL BUDGET. *ENSURING THAT LANGUAGE FOR AN APPROPRIATIONS BILL FOR A STUDY ON NAFLD IS INCLUDED IN THE FINAL FUNDING BILL FOR FISCAL YEAR 2024 *PLANNING A CAPITOL HILL BRIEFING FOR JANUARY 2024 ENTITLED, OBESITY: THE LEADING CAUSE OF NONALCOHOLIC FATTY LIVER DISEASE AND THE MOST URGENT THREAT TO PUBLIC HEALTH TODAY. THIS BRIEFING WILL FEATURE MEDICAL PROFESSIONALS AND PATIENT ADVOCATES TO DISCUSS CURRENT DYNAMICS AROUND OBESITY AND LIVER DISEASE. *ADVOCATES ASKED THAT MEMBERS SUPPORT THE FOLLOWING LEGISLATION LIVING DONOR PROTECTION ACT (S. 377/H.R. 1255), THE SAFE STEP ACT (S. 464/H.R. 2163), THE LIVER ACT (S. 3041/H.R. 5675), AND THE HELP COPAYS ACT (H.R. 5801) PLUS FUNDING REQUESTS FOR NIH, ARPAH, CDC, AND HRSA. |
| Form 990, Part III, Line 4d Description of other program services | (Expenses $ 582,056 including grants of $ 400,000) RESEARCH: AMERICAN LIVER FOUNDATION (ALF) HAS A HISTORY OF COMMITMENT TO RESEARCH FUNDING DATING BACK TO 1979, BUT IN 2023 (AFTER A COVID-RELATED HIATUS) IT ESTABLISHED A DEDICATED RESEARCH DEPARTMENT THAT WILL BUILD A SOLID FOUNDATION TO GROW THE RESEARCH PROGRAM OVER THE NEXT FEW YEARS. PRIORITIES WILL INCLUDE MAKING AN IMPACT ON SERIOUS CHALLENGES SUCH AS INADEQUATE FUNDING LEVELS FOR LIVER RESEARCH AND A SCARCITY OF RESEARCHERS DEVOTED TO THE LIVER FIELD. THIS COMMITMENT WILL RESULT IN IMPROVEMENTS IN THERAPEUTIC OPTIONS AND CLINICAL OUTCOMES FOR PATIENTS. KEY ACCOMPLISHMENTS INCLUDED: *CONDUCTED THE ALF RESEARCH AWARDS PROGRAM, WHICH GARNERED A RECORD 21 LIVER SCHOLAR AND 41 POSTDOCTORAL RESEARCH FELLOWSHIP APPLICATIONS. FURTHER, A NEWLY CONSTITUTED GRANTS REVIEW COMMITTEE REVIEWED THE APPLICATIONS FOR LIVER SCHOLAR AWARDS AND POSTDOCTORAL RESEARCH FELLOWSHIP AWARDS, WHICH WERE AWARDED IN DECEMBER 2023. ALF AWARDED 3 LIVER SCHOLAR AWARDS AND 7 POST-DOCTORAL AWARDS TOTALING $400,000 IN FUNDING. *DEVELOPED A PATIENT REGISTRY THAT WILL BE PROMOTED AMONG ACADEMIC AND INDUSTRY PARTNERS TO HELP IDENTIFY RESEARCH TOPICS AND RECRUIT FOR CLINICAL TRIALS. *PARTICIPATED IN THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASE'S LIVER MEETING. RESEARCH STAFF PREPARED AND PRESENTED A POSTER ABOUT THE PILOT PROGRAM FOR ALF'S SIGNATURE LIVER SCREENING PROGRAM, THINK LIVER THINK LIFE. AS PART OF ALF'S MISSION TO EDUCATE PATIENTS, STAFF ATTENDED SESSIONS AND SUMMARIZED CONTENT FROM THE LIVER MEETING FOR DISTRIBUTION TO ALF'S PATIENT CONSTITUENTS. |
| Form 990, Part III, Line 4d Description of other program services | (Expenses $ 493,265 including grants of $) AMERICAN LIVER FOUNDATION (ALF) HAS A HISTORY OF COMMITMENT TO RESEARCH FUNDING DATING BACK TO 1979, BUT IN 2023 (AFTER A COVID-RELATED HIATUS) IT ESTABLISHED A DEDICATED RESEARCH DEPARTMENT THAT WILL BUILD A SOLID FOUNDATION TO GROW THE RESEARCH PROGRAM OVER THE NEXT FEW YEARS. PRIORITIES WILL INCLUDE MAKING AN IMPACT ON SERIOUS CHALLENGES SUCH AS INADEQUATE FUNDING LEVELS FOR LIVER RESEARCH AND A SCARCITY OF RESEARCHERS DEVOTED TO THE LIVER FIELD. THIS COMMITMENT WILL RESULT IN IMPROVEMENTS IN THERAPEUTIC OPTIONS AND CLINICAL OUTCOMES FOR PATIENTS. KEY ACCOMPLISHMENTS INCLUDED: *CONDUCTED THE ALF RESEARCH AWARDS PROGRAM, WHICH GARNERED A RECORD 21 LIVER SCHOLAR AND 41 POSTDOCTORAL RESEARCH FELLOWSHIP APPLICATIONS. FURTHER, A NEWLY CONSTITUTED GRANTS REVIEW COMMITTEE REVIEWED THE APPLICATIONS FOR LIVER SCHOLAR AWARDS AND POSTDOCTORAL RESEARCH FELLOWSHIP AWARDS, WHICH WERE AWARDED IN DECEMBER 2023. ALF AWARDED 3 LIVER SCHOLAR AWARDS AND 7 POST-DOCTORAL AWARDS TOTALING $400,000 IN FUNDING. *DEVELOPED A PATIENT REGISTRY THAT WILL BE PROMOTED AMONG ACADEMIC AND INDUSTRY PARTNERS TO HELP IDENTIFY RESEARCH TOPICS AND RECRUIT FOR CLINICAL TRIALS. *PARTICIPATED IN THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASE'S LIVER MEETING. RESEARCH STAFF PREPARED AND PRESENTED A POSTER ABOUT THE PILOT PROGRAM FOR ALF'S SIGNATURE LIVER SCREENING PROGRAM, THINK LIVER THINK LIFE. AS PART OF ALF'S MISSION TO EDUCATE PATIENTS, STAFF ATTENDED SESSIONS AND SUMMARIZED CONTENT FROM THE LIVER MEETING FOR DISTRIBUTION TO ALF'S PATIENT CONSTITUENTS. |
| Form 990, Part VI, Line 11b Review of form 990 by governing body | A DRAFT OF THE FORM 990 IS SENT TO THE FINANCE COMMITTEE FOR REVIEW AND COMMENTS IN THE MONTHLY MEETING PRIOR TO FILING. IN ADDITION, A DRAFT OF THE FORM 990 IS ALSO SENT TO EACH BOARD MEMBER FOR DISCUSSION. AFTER QUESTIONS AND COMMENTS ARE ADDRESSED AND THE FORM 990 IS APPROVED, IT IS READY FOR FILING. |
| Form 990, Part VI, Line 12c Conflict of interest policy | ANNUALLY, OUR CONFLICT OF INTEREST FORM IS COMPLETED BY OFFICERS AND DIRECTORS. THE FORM MUST INDICATE ANY POSSIBLE CONFLICTS OF INTEREST AND BE SIGNED BY ALL OFFICERS AND DIRECTORS. WHEN ANY SUCH CONFLICT OF INTEREST IS RELEVANT TO A MATTER REQUIRING ACTION BY THE BOARD, THE INTERESTED PERSON SHALL CALL IT TO THE ATTENTION OF THE BOARD AND SUCH PERSON SHALL NOT VOTE ON THE MATTER. MOREOVER, THE PERSON HAVING A CONFLICT SHALL RETIRE FROM THE ROOM IN WHICH THE BOARD IS MEETING AND SHALL NOT PARTICIPATE IN THE FINAL DELIBERATION OR DECISION REGARDING THE MATTER UNDER CONSIDERATION. HOWEVER, THAT PERSON SHALL PROVIDE THE BOARD WITH ANY AND ALL RELEVANT INFORMATION. THE MINUTES OF THE MEETING OF THE BOARD, SHALL REFLECT THAT THE CONFLICT OF INTEREST WAS DISCLOSED AND THAT THE INTERESTED PERSON WAS NOT PRESENT DURING THE FINAL DISCUSSION OR VOTE AND DID NOT VOTE. WHEN THERE IS A DOUBT AS TO WHETHER A CONFLICT OF INTEREST EXISTS, THE MATTER SHALL BE RESOLVED BY A VOTE OF THE BOARD. |
| Form 990, Part VI, Line 15a Process to establish compensation of top management official | CEO COMPENSATION IS DETERMINED BY THE NATIONAL BOARD OF DIRECTOR'S EXECUTIVE COMMITTEE AND APPROVED BY THE BOARD MEMBERS. IN DETERMINING SALARY LEVELS, THE EXECUTIVE COMMITTEE REVIEWS AN ANNUAL SALARY SURVEY OF NATIONAL VOLUNTARY HEALTH ORGANIZATIONS PREPARED FOR THE NATIONAL HEALTH COUNCIL AND REVIEWS PRIOR YEAR PERFORMANCE. CURRENT MARKET CONDITIONS AND THE FINANCIAL CONDITION OF THE AMERICAN LIVER FOUNDATION ARE ALSO CONSIDERED IN SETTING COMPENSATION. THIS REVIEW WAS LAST CONDUCTED IN 2023. |
| Form 990, Part VI, Line 15b Process to establish compensation of other employees | THE SALARY OF OFFICERS AND KEY EMPLOYEES ARE DETERMINED BY THE CEO AND CFO BASED ON PERFORMANCE, MARKET CONDITIONS AND THE FINANCIAL CONDITION OF THE AMERICAN LIVER FOUNDATION. |
| Form 990, Part VI, Line 19 Required documents available to the public | THE ANNUAL AUDIT REPORT AND FORM 990 ARE AVAILABLE VIA WWW.LIVERFOUNDATION.ORG AND FORM 1023 AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. |
| Software ID: | 23017437 |
| Software Version: | 2023v5.1 |